The efficacy and safety of intra-articular application of a combination of sodium hyaluronate and chondroitin sulfate for osteoarthritis of the knee: a multicenter prospective study
- Authors: Alekseeva L.I.1, Kashevarova N.G.1, Taskina E.A.1, Sharapova E.P.1, Anikin S.G.1, Strebkova E.A.1, Raskina T.A.2, Zonova E.V.3, Otteva E.N.4, Rodionova S.S.5, Torgashin A.N.5, Buklemishev U.V.5, Shmidt E.I.6, Shesternya P.A.7, Naumov A.V.8, Zagorodniy N.V.5, Lila A.M.1
-
Affiliations:
- Nasonova Research Institute of Rheumatology
- Kemerovo State Medical University
- Novosibirsk State Medical University
- Institute of Advanced Training for Health Professionals
- Priorov National Medical Research Center for Traumatology and Orthopedics
- Pirogov Municipal Clinical Hospital №1
- Voyino-Yasenetsky Krasnoyarsk State Medical University
- Pirogov Russian National Research Medical University
- Issue: Vol 92, No 5 (2020)
- Pages: 46-54
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/34585
- DOI: https://doi.org/10.26442/00403660.2020.05.000631
- ID: 34585
Cite item
Full Text
Abstract
in 3 mL on patients with knee osteoarthritis (OA) in a multicenter prospective study.
Materials and methods. 79 outpatients (predominantly females – 81.0%) from 5 RF constituent territories with primary tibiofemoral Kellgren–Lawrence score grade II or III knee OA, ≤40 mm pain intensity during walking on visual analogue scale (VAS), requiring NSAIDs intake (for at least 30 days during 3 months prior to enrollment) were included into the study after signing the informed consent form. Mean age was 60.3±8.7 years, mean BMI – 29.2±4.7 kg/m2, disease duration – 6 (3–10) years. Grade II OA was documented in 68.4% of patients, Grade III – in 31.6%. The study lasted for 6 months. Efficacy and safety evaluations were made based on VAS pain assessment, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) – [WOMAC pain (0–500), WOMAC function (0–1700), WOMAC stiffness (0–200)], VAS patients’ health status, EQ-5D-based assessment of patients’ quality of life, global physician’s and patient’s efficacy assessment, and daily NSAIDs requirements.
Results. Obtained results demonstrate statistically significant VAS pain reduction during walking already in 1 week after intra-articular injection of the combination [respectively, 62 (55–72) and 41 (32–51) mm, р<0.0001]. Moreover, pain continued to subside during all 3 months of follow up [in 1 month – 28 (20–42), in 3 month – 22 (14–37) mm]. A significant pan reduction achieved at Mo 3 persisted until Mo 6 – 20 (14–42) mm, without documented pain increase. Similar trends were observed with total WOMAC score [1125 (899–1540) – at baseline, and 552 (309–837) mm – by the end of the study, p<0.0001], and all WOMAC sub-scores [268 (189–312) – baseline WOMAC pain, 91 (48–171) mm – by the end of the study p<0.0001; stiffness – 101 (59–130) and 40 (20–61) mm, p<0.0001; function – 802 (647–1095) and 402 (191–638) mm, p<0.0001, respectively]. Median time to the onset of therapeutic effect was 7 (5–18) days. Statistically significant improvement of patients’ quality of life by EQ-5D and general health status was observed during all follow up period [respectively, 0.52 (-0.02–0.59) and 0.69 (0.59–0.80), р<0.0001; 48 (30–60) and 72 (60–80) mm, р<0.0001]. One injection of the drug resulted in dose reduction or discontinuation of NSAIDs therapy: at baseline 76 patients (96.2%) were taking NSAIDs, in one week 31 (39.2%) patients discontinued NSAIDs, in 1 month – 72.2%, in 3 months – 73.4%, and by the end of the study at Mo 6 – 54.4% were not taking NSAIDs. These data were consistent with physician’s and patient’s global assessment of the efficacy of treatment, who stated “significant improvement” and “improvement” in the majority of cases, with only few “no effect” or “worsening” cases documented in analyzed population. Adverse events, such as worsening of pain and/or swelling of the joint, were documented in 8 patients (10.1%); they resolved spontaneously or following NSAIDs intake.
Conclusion. These results suggest that intra-articular injections of hyaluronic acid plus chondroitin sulfate in patients with knee OA are efficient and safe. A single injection of the drug resulted in statistically significant reduction of pain and stiffness, reduction in NSAIDs intake, as well as improvement in patients’ quality of life and function.
Full Text
##article.viewOnOriginalSite##About the authors
L. I. Alekseeva
Nasonova Research Institute of Rheumatology
Email: nat-kash@yandex.ru
д.м.н., рук. отд. метаболических заболеваний костей и суставов
N. G. Kashevarova
Nasonova Research Institute of Rheumatology
Author for correspondence.
Email: nat-kash@yandex.ru
ORCID iD: 0000-0001-8732-2720
к.м.н., науч. сотр. отд. метаболических заболеваний костей и суставов
E. A. Taskina
Nasonova Research Institute of Rheumatology
Email: nat-kash@yandex.ru
ORCID iD: 0000-0001-8218-3223
к.м.н., ст. науч. сотр. отд. метаболических заболеваний костей и суставов
E. P. Sharapova
Nasonova Research Institute of Rheumatology
Email: nat-kash@yandex.ru
ORCID iD: 0000-0003-4242-8278
к.м.н., науч. сотр. отд. метаболических заболеваний костей и суставов
Russian Federation, MoscowS. G. Anikin
Nasonova Research Institute of Rheumatology
Email: nat-kash@yandex.ru
ORCID iD: 0000-0001-5643-3196
к.м.н., ст. науч. сотр. отд. метаболических заболеваний костей и суставов
Russian Federation, MoscowE. A. Strebkova
Nasonova Research Institute of Rheumatology
Email: nat-kash@yandex.ru
ORCID iD: 0000-0001-8130-5081
к.м.н., ст. науч. сотр. отд. метаболических заболеваний костей и суставов
T. A. Raskina
Kemerovo State Medical University
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-5804-4298
д.м.н., проф., зав. каф. пропедевтики внутренних болезней
Russian Federation, KemerovoE. V. Zonova
Novosibirsk State Medical University
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-0228-9085
д.м.н., проф. каф. терапии, гематологии и трансфузиологии фак-та повышения квалификации и профессиональной переподготовки врачей
Russian Federation, NovosibirskE. N. Otteva
Institute of Advanced Training for Health Professionals
Email: nat-kash@yandex.ru
д.м.н., проф. каф. терапии и профилактической медицины
Russian Federation, KhabarovskS. S. Rodionova
Priorov National Medical Research Center for Traumatology and Orthopedics
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-2726-8758
д.м.н., рук. научно-клинического центра остеопороза
Russian Federation, MoscowA. N. Torgashin
Priorov National Medical Research Center for Traumatology and Orthopedics
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-2789-6172
к.м.н., ст. науч. сотр.
Russian Federation, MoscowU. V. Buklemishev
Priorov National Medical Research Center for Traumatology and Orthopedics
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-0039-2118
врач
Russian Federation, MoscowE. I. Shmidt
Pirogov Municipal Clinical Hospital №1
Email: nat-kash@yandex.ru
ORCID iD: 0000-0001-8814-9704
к.м.н., зав. ревматологическим отд-нием
Russian Federation, MoscowP. A. Shesternya
Voyino-Yasenetsky Krasnoyarsk State Medical University
Email: nat-kash@yandex.ru
ORCID iD: 0000-0001-8652-1410
д.м.н., проф
Russian Federation, KrasnoyarskA. V. Naumov
Pirogov Russian National Research Medical University
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-6253-621X
д.м.н., проф., зав. лаб. костно-мышечных заболеваний
Russian Federation, MoscowN. V. Zagorodniy
Priorov National Medical Research Center for Traumatology and Orthopedics
Email: nat-kash@yandex.ru
д.м.н., проф., дир.
Russian Federation, MoscowA. M. Lila
Nasonova Research Institute of Rheumatology
Email: nat-kash@yandex.ru
ORCID iD: 0000-0002-6068-3080
д.м.н., проф. дир.
Russian Federation, MoscowReferences
- Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323-30. doi: 10.1136/annrheumdis-2013-204763
- Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis – a disease of the joint as an organ. Arthritis Rheum. 2012;64:1697-707. doi: 10.1002/art.34453
- Legre-Boyer V. Viscosupplementation: techniques, indications, results. Orthop Traumatol Surg Res. 2015;101:S101-S108. doi: 10.1016/j.otsr.2014.07.027
- Pederzini LA, Milandri L, Tosi M, et al. Preliminary clinical experience with hyaluronan anti-adhesion gel in arthroscopic arthrolysis for posttraumatic elbow stiffness. J Orthopaed Traumatol. 2013;14(2):109-14. doi: 10.1007/s10195-013-0229-z
- Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43(5):593-9. doi: 10.1016/j.semarthrit.2013.10.002
- Bannuru RR, Natov NS, Obadan IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:1704-11. doi: 10.1002/art.24925
- He WW, Kuang MJ, Zhao J, et al. Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: A meta-analysis. Int J Surg. 2017;39:95-103. doi: 10.1016/j.ijsu.2017.01.087
- Kogan G, Soltés L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett. 2007;29(1):17-25. doi: 10.1007/s10529-006-9219-z
- Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. doi: 10.1186/s12891-015-0775-z
- Berenbaum F, Grifka J, Cazzaniga S, et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis 2012;71:1454-60. doi: 10.1136/annrheumdis-2011-200972
- Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthrit Rheumat 2005;52(3):779-86. doi: 10.1002/art.20867
- Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthrit Cartil 2004;12(4):269-76. doi: 10.1016/j.joca.2004.01.004
- Bruyere O, Burlet N, Delmas PD, et al. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskel Dis. 2008;9:165. doi: 10.1186/1471-2474-9-165
- Lee YH, Woo JH, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010;30(3):357-63. doi: 10.1007/s00296-009-0969-5
- Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients withosteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin. 2008;24(11):3029-35. doi: 10.1185/03007990802434932
- David-Raoudi M, Deschrevel B, Leclercq S, et al. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: role of p38 and Akt. Arthritis Rheum. 2009;60(3):760-70. doi: 10.1002/art.24302
- Kosińska MK, Ludwig TE, Liebisch G, et al. Articular joint lubricants during osteoarthritis and rheumatoid arthritis display altered levels and molecular species. PLoS ONE. 2015;10:e0125192. doi: 10.1371/ journal.pone.0125192
- Gonçalves G, Melo EG, Gomes MG, et al. Effects of chondroitin sulfate and sodium hyaluronate on chondrocytes and extracellular matrix of articular cartilage in dogs with degenerative joint disease. Arq Bras Med Vet Zootec. 2008;60(1):93-102. doi: 10.1590/S0102-09352008000100014
- Tosun HB, Gürger M, Gümüştaş SA, et al. The effect of sodium hyaluronate-chondroitin sulfate combined solution on cartilage formation in osteochondral defects of the rabbit knee: an experimental study. Ther Clin Risk Manag. 2017;13:523-32. doi: 10.2147/TCRM.S133635
- Maheu E, Zaïm M, Appelboom T, et al. Evaluation of intra articular injections of hyaluronic acid and chondroitine sulfate for knee arthritis treatment: a multicentric pilot study with 3 monts follow-up. National rheumatolgy meeting 2010 (Société Française de Rhumatologie).
- Tosun HB, Gumustas S, Agir I, et al. Comparison of the effects of sodium hyaluronate-chondroitin sulphate and corticosteroid in the treatment of lateral epicondylitis: a prospective randomized trial. J Orthop Sci. 2015;20(5):837-43: doi: 10.1007/s00776-015-0747-z
- Henrotin Y, Hauzeur JP, Bruel P, Appelboom T. Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. BMC Res Notes. 2012;5:407-11. doi: 10.1186/1756-0500-5-407
- Rivera F, Bertignone L, Grandi G, et al. Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. J Orthop Traumatol. 2016;17(1):27-33. doi: 10.1007/s10195-015-0388-1
- Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253-63. doi: 10.1016/j.semarthrit. 2014.05.014
- Baron D, Flin C, Porterie J, et al. Hyaluronic acid single injection in knee osteoarthritis: a multi-center open prospective study (ART-ONE 75) with placebo post-hoc comparison. Cur Ther Res. 2018;88:35-46. doi: 10.1016/j.curtheres.2018.04.001
Supplementary files
![](/img/style/loading.gif)